Literature Collection

We describe a quality improvement study to understand clinicians' perspectives on using a clinical decision support tool (CDS) for clinical diagnosis and education (VisualDx™) across an integrated healthcare system. Surveys, interviews, and secondary data were analyzed to understand the patterns of usage, associated barriers, facilitators, and suggestions influencing the CDS's adoption and usability. Overall, the CDS had multidimensional functionality, and outpatient primary care had the highest adoption. Key benefits included assistance in building differential diagnoses, mainly of 'dermatological conditions', which could be used for patients, students, and clinician self-education. Barriers impacting use were retrospectively mapped to the RE-AIM implementation science framework (e.g., "Reach" or tool-related limited awareness; "Adoption "or access challenges; and "Implementation", and "Maintenance" or sub-optimal training). Incorporating end-user (i.e., clinician) perspectives around factors influencing adoption and use of CDS, under a specific context, could lead to a wider and more successful use.

Objective To describe medical, safety, and health care utilization outcomes associated with an early treatment model for neonatal opioid withdrawal. Study Design This is a retrospective review of 117 opioid-exposed infants born in a large regional hospital and treated in the level I nursery with methadone initiated within 48 hours of birth. Results For this cohort, mean length of stay was 8.3 days. Hospital safety events were infrequent; there were no medication errors or deaths. Within 30 days of discharge, 14% of infants visited the emergency department; 7% were readmitted. Per birth, mean hospital charges were $10,946.96; mean costs were $5,908.93. Conclusion This study is the first to describe an early treatment model in a low-acuity nursery to prevent severe neonatal opioid withdrawal. The described model may be safe, effective, low-cost, and feasible for replication.

Evidence-based digital therapeutics are a promising approach for the scale-up of substance use disorder (SUD) treatments. Despite demonstrated efficacy, utilization of digital therapeutics is low. Strategic implementation approaches have potential for increasing digital therapeutic use. Applicability to health systems depends, in part, on the economic costs. The objective of this study was to describe implementation and intervention costs of implementation strategies to increase uptake of an evidence-based digital treatment for SUD. We conducted an economic evaluation alongside a hybrid type III cluster-randomized trial within a large integrated health system. All clinics implemented a standard implementation (SI) strategy, and clinics were assigned using 2x2 factorial randomization to additionally receive practice facilitation (PF) and/or health coaching (HC). Implementation costs included the cost of time devoted to implementation activities and direct operating costs. Time devoted to implementation activities was ascertained through structured meeting logs and time use surveys. Operating costs were captured using project budget reports. Intervention costs included expenses for prescriptions and healthcare encounters related to the digital therapeutic, measured using electronic health record data. Univariate statistics were calculated for cost estimates with comparisons presented by trial arm, implementation activity, staff role and study month. Analyses were conducted from a health system perspective. Twenty-one primary care sites participated in the trial. Over the 50-month study period, the total cost of all implementation activities was $748,088. Implementation costs per clinic were highest in the SI + PF + HC arm ($48,029), followed by SI + HC ($36,544), SI + PF ($30,665) and SI alone ($24,774). Intervention costs were highest in the SI + PF + HC arm ($18,051), followed by SI + PF ($11,492), SI + HC ($967) and SI alone ($1,879). Findings from this study can guide health systems by informing the economic investment required to employ implementation strategies demonstrated to increase uptake of evidence-based practices for behavioral health conditions. Trial Registration: NCT05160233.